CD40LG and neoplasm: Moreover, the combined immunotherapy seems to be AFP-specific, since vaccination with Ad-AFP-DC combined with i.t.-injection of Ad-CD40L-DC did not differ from a vaccination with Ad-LacZ-DC combined with i.t.-injection of Ad-CD40L-DC in tumor-bearing mice with AFP-negative Hepa129-tumors (Figure 2e,f).